Skip to main content
SpringerLink
Log in

Pirprofen

A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy

  • Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Synopsis: Pirprofen1 is a non-steroidal anti-inflammatory drug, related structurally to drugs such as ibuprofen, ketoprofen and naproxen. Published clinical trials indicate that pirprofen 600 to 1200 mg/day as 2 or 3 divided doses is a suitable alternative to usual therapeutic dosages of aspirin, flurbiprofen, ibuprofen, indomethacin, ketoprofen, naproxen, piroxicam and sulindac in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, musculoskeletal disorders and non-articular rheumatism. More studies are required to evaluate its potential relative to other commonly used drugs in the treatment of gout, juvenile rheumatoid arthritis and dysmenorrhoea. In patients with acute postsurgical, trauma or cancer pain, single oral or intramuscular doses of pirprofen 200 to 400mg provide equivalent analgesic activity to usual therapeutic doses of aspirin, diflunisal, ketoprofen, noramidopyrine, paracetamol and pentazocine. As with other nonsteroidal anti-inflammatory drugs, gastrointestinal complaints are the most frequently reported side effects. At equivalent analgesic or anti-inflammatory dosages, pirprofen probably causes fewer side effects than aspirin and appears to be as well tolerated as the other agents with which it has been compared. Long term tolerability, particularly compared with some of the newer, purportedly less gastrotoxic agents or formulations, needs to be investigated further.

Pirprofen does not appear likely to offer any particular advantage with respect to efficacy and tolerability over other non-steroidal anti-inflammatory drugs, except aspirin. However, as no one agent is the most suitable drug for all patients requiring such therapy, pirprofen may be considered along with other drugs of this type in the therapy of arthritic conditions and acute pain states.

Pharmacodynamic Properties: In experimental animal models, pirprofen has been shown to possess anti-inflammatory, analgesic and antipyretic activities similar to those of several other non-steroidal anti-inflammatory drugs commonly used in the treatment of rheumatic conditions. The ulcerogenic activity of pirprofen in animals appears similar to that of diclofenac, flurbiprofen and indomethacin. The relative gastrointestinal toxicity compared with other non-steroidal anti-inflammatory drugs needs to be investigated further in animals and human subjects. Pirprofen inhibits the secondary phase of platelet aggregation induced by collagen and arachidonic acid in vitro but does not influence ADP-induced primary platelet aggregation in vitro or in vivo. Unlike aspirin whose effect is irreversible, pirprofen is a reversible inhibitor of prostaglandin synthetase in vitro and in vivo. It inhibits the cyclo-oxygenase but not the lipoxygenase pathway of arachidonic acid metabolism. Pirprofen is an inhibitor of leucocyte chemotaxis in vitro and in vivo in man, and it does not adversely affect cartilage in animal models of degenerative joint disease unlike certain other non-steroidal anti-inflammatory drugs.

Pharmacokinetic Properties: Peak plasma concentrations of about 20 mg/L are attained about 1 to 1.5 hours after the oral ingestion of a 200mg dose of pirprofen in man; pharmacokinetics are linear over a dose range from 50 to 600mg. The rate of absorption is slowed by food or concomitant antacid administration, although the extent of absorption is unaffected. Steady-state plasma concentrations are achieved after 3 to 4 doses administered every 6 to 8 hours. The pharmacokinetics of pirprofen best fit a 2-compartment model: the total apparent volume of distribution is 8 to 12L, and that of the central compartment is 5L, where the drug is extensively bound (> 99.5%) to plasma proteins. Pirprofen diffuses into synovial fluid where relatively stable concentrations are maintained despite fluctuations in plasma concentration during repeated oral doses. The drug is extensively metabolised in the liver, and 11 metabolites have been identified in human urine. The major metabolites do not possess pharmacological activity. Unchanged drug and metabolites are excreted primarily as glucuronide conjugates in urine. 80% of a radiolabelled dose is excreted in urine and 8% in faeces over 24 hours. The elimination half-life is 6 to 7 hours and plasma clearance is 1.2 L/h. In patients with severe renal impairment, the half-life of pirprofen is prolonged to about 10 hours.

Therapeutic Trials: In patients with rheumatoid arthritis and osteoarthritis, pirprofen 600 to 1200 mg/day is at least as effective and as well tolerated as aspirin 3600 mg/day, flurbiprofen 300 mg/day, ibuprofen 1200 mg/day, indomethacin 75 to 150 mg/day, ketoprofen 200 to 300 mg/day, naproxen 500 to 1000 mg/day, piroxicam 20 mg/day and sulindac 400 mg/day. Comparisons with aspirin were generally long term and demonstrated that pirprofen was better tolerated at equivalent anti-inflammatory dosages. Comparisons with other non-steroidal anti-inflammatory drugs were mainly of short duration (1 to 6 weeks). Longer term comparative trials are therefore required and, although unlikely to show differences in efficacy at optimal dosages, differences in relative tolerability might be revealed. In ankylosing spondylitis pirprofen 750 to 1000 mg/day appears as effective as indomethacin up to 125 mg/day and ketoprofen 300 mg/day. Open studies in patients with gout and juvenile rheumatoid arthritis have yielded encouraging results but comparative studies are required to determine the role of pirprofen in these conditions.

Pirprofen 800 to 1200 mg/day is as effective as indomethacin 100 to 150 mg/day, ketoprofen 300 mg/day and piroxicam 20 mg/day in the short term (1 to 2 weeks) treatment of pain and inflammation associated with acute musculoskeletal disorders and non-articular rheumatism. Pirprofen 600 to 800 mg/day is effective in relieving pain and other symptoms associated with dysmenorrhoea but studies are required to determine its efficacy relative to other agents more commonly used in this condition.

In moderate to severe pain (postsurgical, trauma, cancer), single oral doses of pirprofen 200 to 400mg are at least as effective as aspirin 650 to 900mg, diflunisal 500mg, ketoprofen 150mg, oxyphenbutazone 250mg, paracetamol 650mg, pentazocine 100mg and zomepirac 100mg. With intramuscular administration, a single dose of pirprofen 400mg is more effective in relieving pain than noramidopyrine 1000mg but less effective than pentazocine 60mg. Intramuscular pentazocine, however, produced more centrally mediated side effects such as nausea and vomiting.

Side Effects: Pirprofen has been well tolerated in most patients to date. However, further data are required to determine its side effect profile more clearly in patients receiving long term therapy, particularly when compared with other frequently used non-steroidal anti-inflammatory drugs. The most frequent side effects are mild gastrointestinal complaints, followed less frequently by mild central nervous system and cutaneous effects. Both the frequency and nature of side effects appear similar to other non-steroidal anti-inflammatory drugs. Pirprofen is probably less likely to cause gastrointestinal effects and tinnitus than aspirin. It may produce fewer central nervous system effects than indomethacin, but tends to produce more gastrointestinal complaints. Pirprofen-induced hepatitis has been reported in several patients receiving long term therapy.

Dosage: The usual starting dosage of pirprofen is 800 mg/day in 2 divided doses, and once improvement has occurred 600 mg/day may prove sufficient for maintenance therapy. An initial dosage of 1200 mg/day in 3 divided doses can be administered for 1 to 2 weeks in patients with rheumatoid arthritis or ankylosing spondylitis. For the relief of pain, the single dose is 200 to 400mg depending on pain severity up to a maximum of 1200 mg/day. Pirprofen 400mg can be administered intramuscularly for severe acute pain followed after several hours by another injection if necessary; once the pain has abated, the patient should be transferred to oral medication. The usual precautions and contraindications to non-steroidal anti-inflammatory drug therapy apply to pirprofen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adair SF, Eisner CW, Patel HI, Marshall JR. Dysmenorrhea treated with pirprofen — a double-blind, placebo-controlled trial. Abstract no. P87 presented at the 16th International Congress of Rheumatology, Sydney, 19–25 May, 1985

  • Akinci E, Ertürk M, Yosmaoglu A, Sengir O. A comparative multicentre study of pirprofen, naproxen, and placebo in the treatment of osteoarthrosis of the lumbar spine. In van der Korst (Ed.) Pirprofen in the light of recent experience, pp. 76–85, Hans Huber Publishers, Bern, 1985

    Google Scholar 

  • Akita S, Satoh M, Takagi H. Effect of pirprofen on bradykinininduced flexor reflexes of rat and rabbit hindlimbs. Folia Pharmacologica Japonica 86: 257–260, 1985

    PubMed  CAS  Google Scholar 

  • Astapenko MG. Pirprofen and piroxicam in osteoarthritis of the hip and/or knee. In Nassonova (Ed.) Pirprofen (®Rengasil) —an update, pp. 63–68, Hans Huber Publishers, Bern, 1984

    Google Scholar 

  • Ayrolles C, Fournie A. Utilisation du pirprofène dans le traitement de la polyarthrite rhumatoïde (P.R.). Nouvelle Presse Médicale 11: 2487–2490, 1982

    PubMed  CAS  Google Scholar 

  • Bachmann F, Hartl PW. Initialtherapie der aktivierten Cox — und Gonarthrose mit Pirprofen: Dopplblindstudie versus Indometacin. Fortschritte der Medizin 103: 179–181, 1985

    PubMed  CAS  Google Scholar 

  • Bandilla K, Greif G. A double-blind 6 months study of pirprofen versus indomethacin in patients with osteoarthrosis. Abstract presented at the 16th International Congress of Rheumatology, Sydney, 19–25 May, 1985

  • Bartlett MF, Egger H, Luders RC, Maggio-Cavaliere MB, Resnick O. Physiological disposition of SV 21524 in man. Abstract. Proceedings of the 3rd Annual Meeting of the American College of Clinical Pharmacology, Atlantic City, New Jersey, 4 May, 1974

  • Bass JC, Brewer EJ, Giannini EH, Athreya BH, Goldsmith DP, et al. A four-week multicentre trial of pirprofen in juvenile rheumatoid arthritis with a long-term follow-up. In van der Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 52–57, Hans Huber, Bern, 1982a

    Google Scholar 

  • Bass JC, Giannini EH, Brewer EJ, Athreya BH, Brandstrup NE, et al. Pirprofen (Rengasil®) in the treatment of juvenile rheumatoid arthritis. Journal of Rheumatology 9: 140–143, 1982b

    PubMed  CAS  Google Scholar 

  • Bhattacherjee P, Eakins KE. Inhibition of the ocular effects of sodium arachidonate by anti-inflammatory compounds. Prostaglandins 9: 175–182, 1975

    PubMed  CAS  Google Scholar 

  • Bito LZ, Salvador EV. Effects of anti-inflammatory agents and some other drugs on prostaglandin biotransport. Journal of Pharmacology and Experimental Therapeutics 198: 481–488, 1976

    PubMed  CAS  Google Scholar 

  • Blechman WJ, et al. An open label multicenter study of the efficacy and safety of pirprofen in rheumatoid arthritis. Abstract no. 959 presented at the 14th International Congress of Rheumatology, San Francisco, 26 Jun–1 Jul, 1977

  • Bloomfield SS, Barden TP, Mitchell J. A comparison of pirprofen, aspirin, acetaminophen, and placebo in postpartum uterine cramp pain. Current Therapeutic Research 30 (Suppl.): S139–S145, 1981

    Google Scholar 

  • Bodem H. Kupierung des akuten Gichtanfalls. Fortschritte der Medizin 103: 203–206, 1985

    PubMed  CAS  Google Scholar 

  • Bona L, Pollavini S, Monza G. Controlled trial of two nonsteroidal anti-inflammatory drugs in postoperative pain relief: a 12-hour evaluation. Clinical Therapeutics 7: 474–479, 1985

    PubMed  CAS  Google Scholar 

  • Bonomo I, Chahade WH, Gramajo RJ. A multicentre double-blind trial of pirprofen, ibuprofen, and placebo in osteoarthritis of the spine. In van der Korst (Ed.) A new antirheumaticanalgesic agent pirprofen (Rengasil®), pp. 97–101, Hans Huber, Bern, 1981

    Google Scholar 

  • Bruni G, Dal Pra P, Dotti MT, Segre G. Effect of various antiinflammatory drugs on plasma ACTH and cortisol levels in rats. Pharmacological Research Communications 12: 349–357, 1980

    PubMed  CAS  Google Scholar 

  • Buckert D. Analgesic effect of pirprofen in pain due to malignant disease. In van der Korst (Ed.) A new antirheumatic-analgesic agent pirprofen (Rengasil®), pp. 28–33, Hans Huber, Bern, 1981

    Google Scholar 

  • Buckert D. Effet analgésique du pirprofène dans la douleur des affections malignes. Nouvelle Presse Médicale 11: 2511–2513, 1982

    PubMed  CAS  Google Scholar 

  • Butler M, Colombo C, Hickman L, O’Byrne E, Steele R, et al. A new model of osteoarthritis in rabbits. Arthritis and Rheumatism 26: 1380–1386, 1983

    PubMed  CAS  Google Scholar 

  • Calin A, McShane D, Powers R. Objective measurements in evaluating drug therapy in ankylosing spondylitis. Current Therapeutic Research 24: 838–842, 1978

    Google Scholar 

  • Camus J-P. A dose-finding trial with pirprofen in rheumatoid arthritis. In van der Korst (Ed.) A new antirheumatic-analgesic agent pirprofen (Rengasil®), pp. 66–71, Hans Huber, Bern, 1981

    Google Scholar 

  • Camus J-P, Prier A. Traitement de la polyarthrite rheumatoïde par pirprofène: comparaison de deux posologies. Nouvelle Presse Médicale 11: 2481–2483, 1982

    PubMed  CAS  Google Scholar 

  • Cascio V, Cozzi S, Maresca V, Monza GC. The antiinflammatory and analgesic effects of pirprofen in plastic surgery: a double-blind study. Current Therapeutic Research 38: 147–151, 1985

    Google Scholar 

  • Castot A, Netter P, Arnaudo J-P, Andrieu J, Vicari F, et al. Hépatites au pirproféne d’évolution favorable: a propos de 5 observations. Thérapie 39: 297–303, 1984

    PubMed  CAS  Google Scholar 

  • Cavaretta CP. A long-term double-blind comparison of acetylsalicylic acid in rheumatoid arthritis. In van der Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 35–43, Hans Huber, Bern, 1982

    Google Scholar 

  • Cervio N. Efficacy of a twice-daily pirprofen regimen in osteoar-throsis of the hip. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 43–46, Hans Huber, Bern, 1981

    Google Scholar 

  • Chart JJ, Maier R. A brief review of the pre-clinical pharmacology of pirprofen. In van der Korst (Ed.) A new antirheumaticanalgesic agent: pirprofen (Rengasil®), pp. 14–21, Hans’Huber, Bern, 1981

    Google Scholar 

  • Chart JJ, Steinetz BG, Stecher VJ, Howie N. Pharmacological evaluation of pirprofen: a potent anti-inflammatory agent. Current Therapeutic Research 30 (Suppl.): S76–S89, 1981

    Google Scholar 

  • Colombo C, Butler M, Hickman L, Selwyn M, Chart J, et al. A new model of osteoarthritis in rabbits. Arthritis and Rheumatism 26: 1132–1139, 1983

    PubMed  CAS  Google Scholar 

  • Colussi D, Marfil F, Sioufi A. Simultaneous determination of pirprofen and its metabolite, the pyrrole derivative, in plasma by high-performance liquid chromatography. Journal of Chromatography 339: 157–162, 1985

    PubMed  CAS  Google Scholar 

  • Colussi D, Sioufi A. Interaction in vitro, au niveau de la liaison proteinique, du pirprofen et de la sulfinpyrazone avec l’acenocoumarol. In Aiache & Hirtz (Eds) First European Congress of Biopharmaceutics and Pharmacokinetics, Vol. 2, pp. 344–352, 1981

    Google Scholar 

  • Crouzet J. Pirprofen in the treatment of non-articular rheumatism. In van der Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 66–73, Hans Huber, Bern, 1982a

    Google Scholar 

  • Crouzet J. Traitement des rhumatismes extra-articulaires par le pirprofène. Nouvelle Presse Médicale 11: 2503–2505, 1982b

    PubMed  CAS  Google Scholar 

  • Danan G, Trunet P, Bernuau J, Degott C, Babany G, et al. Pirprofen-induced fulminant hepatitis. Gastroenterology 89: 210–213, 1985

    PubMed  CAS  Google Scholar 

  • Daubresse AJ. Pirprofen for the treatment of rheumatic disorders and post-traumatic lesions. Acta Therapeutica 10: 97–104, 1984

    Google Scholar 

  • David-Chaussé J. Etude de la tolérance du pirprofène lors de traitements prolongés. Nouvelle Presse Médicale 11: 2522–2524, 1982

    PubMed  Google Scholar 

  • Davis JD, Struth AG, Turner RA, Pisko EJ, Ruchte IR. Pirprofen and aspirin in the treatment of rheumatoid arthritis. Clinical Pharmacology and Therapeutics 25: 618–623, 1979

    PubMed  CAS  Google Scholar 

  • de Sèze S. Étude comparative du pirprofène et kétoprofène en traitement prolongé. Vie Médicale 19: 873–878, 1983

    Google Scholar 

  • Diverse P, Franchimont P. Clinical trial of pirprofen in arthrosis of the knee joint: a double-blind comparison with indomethacin. Journal of International Medical Research 11: 218–221, 1983

    PubMed  CAS  Google Scholar 

  • Dolanc B, Morscher E. Etude comparative en double insu du pirprofène, de l’indométacine et d’un placebo dans le traitement de l’arthrose vertébrale. Nouvelle Presse Médicale 11: 2500–2502, 1982

    PubMed  CAS  Google Scholar 

  • Dolanc B, Morscher E. Pirprofen compared with indomethacin and placebo in osteoarthritis of the spine. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 36–42, Hans Huber, Bern, 1981

    Google Scholar 

  • Domenget JF, Laseur M, Blanc P, Fogliani J. Insuffisance rénale aiguë et syndrome néphrotique liés au pirprofène. Presse Médicale 13: 283, 1984

    CAS  Google Scholar 

  • Droste U. Pirprofen in der Behandlung der ankylosierenden Spondylitis: offene Prüfung über drei Wochen. Fortschritte der Medizin 103: 173–175, 1985

    PubMed  CAS  Google Scholar 

  • Droste U, Siemens P. Pirprofen in ankylosing spondylitis. Abstract no. 569 presented at the 10th European Congress of Rheumatology, Moscow, 26 Jun–2 Jul, 1983

  • Egger H, Bartlett F, Yuan H-P, Karliner J. Metabolism of pirprofen in man, monkey, rat and mouse. Drug Metabolism and Disposition 10: 529–536, 1982

    PubMed  CAS  Google Scholar 

  • Eidsaunet W. Efficacy and tolerability of pirprofen, naproxen, and placebo in active RA. Abstract presented at the 16th International Congress of Rheumatology, Sydney, 19–25 May, 1985

  • El Badawy SA. Assessment of pirprofen and naproxen in the management of active rheumatoid arthritis. In van der Korst (Ed.) Pirprofen in the light of recent experience, pp. 52–65, Hans Huber, Bern, 1985

    Google Scholar 

  • Eisner CW, Adair SF, Patel HI, Marshall JR. Pirprofen in dysmenorrhea: a double-blind, placebo-controlled trial. Abstract. Clinical Pharmacology and Therapeutics 27: 251–252, 1980

    Google Scholar 

  • Ferreira SH, Moncada S, Vane JR. Prostaglandins and signs and symptoms of inflammation. In Robinson and Vane (Eds) Prostaglandin synthetase inhibitors, pp. 175–187, Raven Press, New York, 1974

    Google Scholar 

  • Fiore-Donno G, Pardinas M, Nekora A. A dose-finding trial with pirprofen in postoperative pain after oral surgery. Journal of Hospital Dental Practice 13: 77–80, 1979

    PubMed  CAS  Google Scholar 

  • Fouin-Fortunet H, Lerebours E, Bernet J, Hemet J, Colin R. Hépatite au pirprofène. Annales de Gastroenterologie et d’Hepatologie 22: 23–25, 1986

    PubMed  CAS  Google Scholar 

  • Gerard MJ, Corrion F. A comparative trial of pirprofen and ketoprofen in rheumatoid arthritis. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 109–113, Hans Huber, Bern, 1981

    Google Scholar 

  • Gerard MJ, Serrurier D. Pirprofene en rheumatologie: etude chez 12217 malades. Rhumatologie 35: 293–297, 1983

    Google Scholar 

  • Gerardin A, Luders RC, Wagner Jr WE. Absorption kinetics and model characteristics of orally administered pirprofen. Journal of Pharmacokinetics and Biopharmaceutics 11: 425–433, 1983

    PubMed  CAS  Google Scholar 

  • Goebel KM. Essai comparatif en double insu du pirprofène, de l’indométacine et d’un placebo dans la polyarthrite rhumatoïde. Nouvelle Presse Médicale 11: 2484–2486, 1982

    PubMed  CAS  Google Scholar 

  • Goebel KM. Pirprofen and indomethacin in rheumatoid arthritis — a randomised double-blind trial versus placebo. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 72–83, Hans Huber, Bern, 1981

    Google Scholar 

  • Grasedyck K. Interindividuelle Doppelblindprüfung von Pirprofen versus Indometacin bei Patienten mit chronischer Polyarthritis. Abstract no. 156. Zeitschrift für Rheumatologie 43: 227, 1984

    Google Scholar 

  • Grasedyck K, Filchner R, Gross W. Behandlung der chronischen Polyarthritis mit Pirprofen oder Indometacin. Fortschritte der Medizin 103: 170–172, 1985

    PubMed  CAS  Google Scholar 

  • Guidet M. Apport du pirprofène dans le traitement médical des névralgies radiculaires. Nouvelle Presse Médicale 11: 2506–2510, 1982

    PubMed  CAS  Google Scholar 

  • Gum OB, Luders RC. The pharmacokinetics of pirprofen. Current Therapeutic Research 30 (Suppl.): S118–S122, 1981

    Google Scholar 

  • Häringer E. Pirprofen versus piroxicam in acute spondylitic pain syndromes. In van der Korst (Ed.) Pirprofen in the light of recent experience, pp. 45–51, Hans Huber, Bern, 1985a

    Google Scholar 

  • Häringer E. Therapie akuter spondylogener Schmerzsyndrome in der allgemeinärzlichen Praxis: eine Doppelblindprüfung gegenüber Piroxicam. Fortschritte der Medizin 103: 189–192, 1985b

    PubMed  Google Scholar 

  • Heimstadt P, Bückert C. Behandlung des extraartikulären Rheumatismus: Doppelblindstudie mit Pirprofen und Indometacin. Fortschritte der Medizin 103: 200–202, 1985

    PubMed  CAS  Google Scholar 

  • Hirtz J, Bartlett MF. The pharmacokinetics of pirprofen. In van der Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 16–29, Hans Huber, Bern, 1982

    Google Scholar 

  • Hirtz J, Sioufi A, Gerardin A. Comparative pharmacokinetics of pirprofen in plasma and synovial fluid. In Nassonova (Ed.) Pirprofen (Rengasil®) — an update, pp. 21–27, Hans Huber, Bern, 1984

    Google Scholar 

  • Hoffman R, Bucher UM. Schmerzhafte Erkrankungen des Bewegungsapparates. Informierte Arzt 6: 59–64, 1985

    Google Scholar 

  • Hultin M, Olander K-J. Comparison of pirprofen, acetylsalicylic acid, and placebo in post-operative pain after oral surgery. In van der Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 74–79, Hans Huber, Bern, 1982

    Google Scholar 

  • Jajic I. Pirprofen in patients with diabetes mellitus receiving glibenclamide or chlorpropamide. In Nassonova (Ed.) Pirprofen (Rengasil®) — an update, pp. 40–50, Hans Huber, Bern, 1984

    Google Scholar 

  • Jajic I, Nekora A, Chaudri HA. A double-blind comparison of pirprofen, indomethacin, and placebo in ankylosing spondylitis. In van der Korst (Ed.) A new antirheumatic-analgesic: pirprofen (Rengasil®), pp. 47–55, Hans Huber, Bern, 1981a

    Google Scholar 

  • Jajic I, Nekora A, Chaudri HA. Pirprofène, indométacine et placebo dans la spondylarthrite ankylosante. Nouvelle Presse Médicale 11: 2491–2493, 1982

    PubMed  CAS  Google Scholar 

  • Jajic I, Nekora A, Chaudri HA. Treatment with pirprofen and sulindac in osteoarthrosis of the spine: a double-blind placebo-controlled trial. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 102–108, Hans Huber, Bern, 1981b

    Google Scholar 

  • Jaques R. Antagonism of non-steroidal anti-inflammatory drugs and narcotic analgesics against ethacrynic acid induced writhing. Arzneimittel-Forschung 27: 1698–1700, 1977

    PubMed  CAS  Google Scholar 

  • Josef H, Chahade WH, Chaudri HA. A comparative trial of pirprofen and ibuprofen in rheumatoid arthritis. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 114–118, Hans Huber, Bern, 1981

    Google Scholar 

  • Khan MA. Pirprofen (Rengasil) in the treatment of soft tissue rheumatism. Abstract no. P64 presented at the 16th International Congress of Rheumatology, Sydney, 19–25 May, 1985

  • Klipper AR, Kolodny AL. A multicenter double-blind comparison of pirprofen and aspirin in osteoarthritis. Current Therapeutic Research 30 (Suppl.): S132–S138, 1981

    Google Scholar 

  • Knüsel O, Düggelin S. Medikamentöse Behandlung von Kreuzschmerzen. Informierte Arzt 6: 161–168, 1985

    Google Scholar 

  • Kontomerkos A, Lazaridis J, Dantis P, Georgiadis A. Pirprofen compared with placebo in osteoarthrosis of the hip and of the knee joints. Abstract no. 570 presented at the 10th European Congress of Rheumatology, Moscow, 26 Jun–2 Jul, 1983

  • Krelj AA. Pirprofen compared with naproxen in osteoarthritis of the lumbar spine. In Nassonova (Ed.) Pirprofen (Rengasil®) —an update, pp. 69–79, Hans Huber, Bern, 1984

    Google Scholar 

  • Ku EC, Signor C, Eakins KE. Antiinflammatory agents and inhibition of ocular prostaglandin synthetase. In Samuelsson and Paoletti (Eds) Advances in Prostaglandin and Thromboxane Research Vol. 2, pp. 819–823, Raven Press, New York, 1976

    Google Scholar 

  • Ku EC, Wasvary JM. Inhibition of prostaglandin synthetase by pirprofen: studies with sheep-seminal vesicle enzyme. Biochimica et Biophysica Acta 384: 360–368, 1975

    PubMed  CAS  Google Scholar 

  • Ku EC, Wasvary JS, Court RH, Wasvary JM. Properties of bovine brain prostaglandin synthetase and its susceptibility to inhibition by nonsteroidal antiinflammatory agents. Abstract no. 2139. Federation Proceedings 33: 590, 1974

    Google Scholar 

  • Kummer H, Nekora A. The analgesic effect of single intramuscular injections of pirprofen, pentazocine, and placebo in malignant disease. In van der Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 80–85, Hans Huber, Bern, 1982

    Google Scholar 

  • Kummer H, Nekora A. Pirprofen in the treatment of rheumatic diseases: a review of comparative trials with indomethacin, naproxen, and piroxicam. In van der Korst (Ed.) Pirprofen in the light of recent experience, pp. 24–38, Hans Huber, Bern, 1985

    Google Scholar 

  • Levin JM. Pirprofen: a new nonsteroidal anti-inflammatory drug for rheumatoid arthritis. Clinical Therapeutics 1: 294–302, 1978

    Google Scholar 

  • Loizzi P, Muratore M, Baroni L. Ricerca controllata con C2T524 Su (pirprofen) a confronto con naproxen in pazienti affetti da A.R. Reumatismo 33: 295–298, 1981

    Google Scholar 

  • Luders RC, Chao D. Effect of pirprofen on protein binding of warfarin and tolbutamide in human plasma. Journal of Pharmaceutical Sciences 70: 1370–1371, 1981

    PubMed  CAS  Google Scholar 

  • Luders RC, Bartlett MF, Maggio-Cavaliere MB, Chao DK, Gum OB, et al. Effect of aspirin on the disposition of pirprofen in man. Current Therapeutic Research 31: 413–421, 1982

    CAS  Google Scholar 

  • Luders RC, Maggio-Cavaliere MB, Egger H, Gum OB, Resnick O, et al. Disposition of pirprofen, a new anti-inflammatory drug. Clinical Pharmacology and Therapeutics 21: 721–730,1977

    PubMed  CAS  Google Scholar 

  • Maggio-Cavaliere MB, Bonus L, Gum OB. A dual approach to the evaluation of the efficacy of a new rheumatoid arthritic agent — pirprofen. Journal of Clinical Pharmacology 16: 8–18, 1976

    PubMed  CAS  Google Scholar 

  • Maggio-Cavaliere MB, Luders RC, Gum OB. Human absorption and elimination of pirprofen. Abstract. Journal of Clinical Pharmacology 15: 563, 1975

    Google Scholar 

  • Maier R. Preclinical findings with pirprofen. In Nassonova (Ed.)Pirprofen (Rengasil®) — an update, pp. 13–20, Hans Huber, Bern, 1984

    Google Scholar 

  • Maier R. Animal experimental data on pirprofen. In van der Korst (Ed.) Pirprofen in the light of recent experience, pp. 11–23, Hans Huber, Bern, 1985

    Google Scholar 

  • Maier R, Schweizer A, Wilhelmi G. Pharmacological aspects of pirprofen. Presented at the 15th International Congress of Rheumatology, Paris, 1981

  • Maier R, Wilhelmi G. Influence of anti-inflammatory drugs on spontaneous osteoarthritis in mice. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 87–96, Hans Huber, Bern, 1981

    Google Scholar 

  • Manz G. Pirprofen bei Patienten mit Arthrosen: Doppelblindstudie versus Indometacin. Fortschritte der Medizin 103: 176–178, 1985

    PubMed  CAS  Google Scholar 

  • Marbet GA, Duckert F, Schönenberger PM. A study on interactions between pirprofen and phenprocoumon (Marcoumar®). In van der Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 30–34, Hans Huber, Bern, 1982

    Google Scholar 

  • Marbet GA, Duckert F, Schönenberger PM. Eine Untersuchung über Wechselwirkungen zwischen Pirprofen und Phenprocoumon. Fortschritte der Medizin 103: 207–209, 1985

    PubMed  CAS  Google Scholar 

  • Martinez-Elizondo P, Cancino-León A, García-Rubio R, Morales-Torres J, Orozco-Alcalá J, et al. Efficacy of intramuscularly administered pirprofen in acute gout. In van der Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 58–65, Hans Huber, Bern, 1982

    Google Scholar 

  • Marty C. Pirprofene en rheumatologie: efficacite et tolerance etude chez 35809 malades. Gazette Médicale de France 91: 102–105, 1984

    Google Scholar 

  • Meineri C, Lestani J, Gentiletti A. Ensayo de un nuevo analgésico-antiinflamatorio: C 21’524-Su en osteoarthritis de cadera y de rodilla. Orientacion Medica 27: 365–367, 1978

    Google Scholar 

  • Méndez Villasénor FJ. Pirprofen oral en dismenorrea primaria. Compendium de Investigaciones Clinicas Latinoamericanas 5: 8–11, 1985

    Google Scholar 

  • Mintz G, Jiménez-Balderas J, Robles E. A short-term double-blind trial comparing pirprofen, indomethacin, and placebo in rheumatoid arthritis. In van der Korst (Ed.) A new antirheumatic — analgesic agent: pirprofen (Rengasil®), pp. 119–123, Hans Huber, Bern, 1981

    Google Scholar 

  • Monza GC, Grossi E, Sacerdoti P, Galante G, Avvisati O. Pirprofen: basic and clinical studies on a possible central mechanism of action. Abstract presented at the 16th International Congress of Rheumatology, Sydney, 19–25 May, 1985

  • Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA. Effect of pirprofen on glibenclamide kinetics and response. British Journal of Clinical Pharmacology 14: 123–126, 1982

    PubMed  CAS  Google Scholar 

  • Müller-Fassbender HR, Schlegel H, Sintohauf U. Behandlung radikulärer Kompressionssyndrome: offene Vergleichsstudie mit Pirprofen und einem Metamizol-Vitamin-B-Komplex. Fort-schritte der Medizin 103: 193–196, 1985

    Google Scholar 

  • Nagura J, Inagaki N, Mori H, Koda A. A study on the anti-allergic action of anti-inflammatory drugs. Abstract no. 0-105. Japanese Journal of Pharmacology 31: 115, 1981

    Google Scholar 

  • Novoa-Heckel G. Pirprofén en la práctica diaria. Investigation Médica Internacional 11: 3–9, 1984

    Google Scholar 

  • Parivisutt L. A double-blind comparative study of pirprofen and naproxen in rheumatoid arthritis. In van der Korst (Ed.) Pirprofen in the light of recent experience, pp. 39–44, Hans Huber, Bern, 1985

    Google Scholar 

  • Peters P, Cooper C, Maiorana K, Graeme ML. The effect of topically applied agents on ultraviolet erythema in guinea-pigs. Agents and Actions 7: 545–553, 1977

    PubMed  CAS  Google Scholar 

  • Peyron J, Doury P. Etude comparative du pirprofene et du kétoprofène dans le traitement de la coxarthrose et de la gonarthrose. Nouvelle Presse Médicale 11: 2497–2499, 1982

    PubMed  CAS  Google Scholar 

  • Pflum LR, Graeme ML. The Arthus reaction in rats, a’ possible test for anti-inflammatory and antirheumatic drugs. Agents and Action 9: 184–189, 1979

    CAS  Google Scholar 

  • Proctor JD, Evans EF, Campos V, Valandia J, Pollack D, et al. Tolerance to pirprofen and preliminary efficacy trial in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 16: 69–76, 1974

    PubMed  CAS  Google Scholar 

  • Proctor JD, Evans EF, Velandia J, Wasserman AJ. Human tolerance, pharmacokinetics and efficacy in rheumatoid arthritis of 2-[3-chloro-4-(3-pyrrolin-l-yl)-phenyl] propionic acid. Abstract. Clinical Pharmacology and Therapeutics 14: 143–144, 1973

    Google Scholar 

  • Reid RT. Pirprofen and aspirin in rheumatoid arthritis: a double-blind comparison study. Journal of Clinical Pharmacology 20: 145–150, 1980

    PubMed  CAS  Google Scholar 

  • Renier J-C, Fournier M, Loyau G, Roux H. Spondylarthrite ankylosante: essai comparatif de deux anti-inflammatoires non stéroïdiens, le pirprofène et le ketoprofène. Nouvelle Presse Médicale 11: 2494–2496, 1982

    PubMed  CAS  Google Scholar 

  • Riess W. Contribution to discussion. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 79–83, Hans Huber, Bern, 1979

    Google Scholar 

  • Rooney L, Kendall MJ, Main A, Hosie J, John VA. Pharmacokinetics of pirprofen in young volunteers and elderly patients. European Journal of Clinical Pharmacology 29: 73–77, 1985

    PubMed  CAS  Google Scholar 

  • Rossi FA, Cavallo F, Baroni L. Low-dosage therapy with pirprofen and naproxen in rheumatoid arthritis. Abstract presented at the Rengasil® Symposium, Paris, 1981

  • Roth H. A multicenter double-blind comparison of pirprofen and aspirin in rheumatoid arthritis. Current Therapeutic Research 30 (Suppl.): S123–S131, 1981

    Google Scholar 

  • Roth H, Levasseur YJ, Ryan R. A controlled, multicenter, twelvemonth study of pirprofen and acetylsalicylic acid in rheumatoid arthritis. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 58–65, Hans Huber, Bern, 1981

    Google Scholar 

  • Roth H, Levasseur Y-J, Ryan R. Activité thérapeutique comparée du pirprofene et de l’acide acétylsalicylique dans le traitement de la polyarthrite rhumatoide. Nouvelle Presse Médicale 11: 2517–2521, 1982

    PubMed  CAS  Google Scholar 

  • Roux H, Vignon G, Delcambre B, Simon L. Comparaison du pirprofene a 4 autres anti-inflammatoires non steroidiens dans le traitement de la polyarthrite rheumatoide. Rhumatologie 35: 113–117, 1983

    Google Scholar 

  • Rowe HJ. Comparison of pirprofen with aspirin in rheumatoid arthritis: a multicenter study. Clinical Therapeutics 2: 69–76, 1978

    Google Scholar 

  • Sacerdote P, Monza G, Mantegazza P, Panerai AE. Diclofenac and pirprofen modify pituitary and hypothalamic beta-endorphin concentrations. Pharmacological Research Communications 17: 679–684, 1985

    PubMed  CAS  Google Scholar 

  • Saggio F, Maresca V, Monza GC. Pirprofen in acute ocular inflammation: a controlled study. Current Medical Research and Opinion 9: 697–700, 1985

    PubMed  CAS  Google Scholar 

  • Saggio F, Monza G. Pirprofen in postoperative course following cataract extraction: a controlled trial. Drugs under Experimental and Clinical Research 11: 735–738, 1985

    PubMed  CAS  Google Scholar 

  • Salzmann G, Sarfert D, Moeller-Orth I. Abstract no. P88 presented at the 16th International Congress of Rheumatology, Sydney, 19–25 May, 1985

  • Saykaly RJ, Love DW, Simon JA, DeGuzmann R, Gabovitch E. Comparative efficacy of pirprofen and aspirin in rheumatoid arthritis. Journal of Clinical Pharmacology 19: 56–63, 1979

    PubMed  CAS  Google Scholar 

  • Schoeller JP, Schwarzberg C, Gerardin A, Colussi D, Sioufi A, et al. Elimination comparée du pirprofène à partir du plasma et du liquide synovial du genou. Presse Médicale 12: 2045–2047, 1983

    CAS  Google Scholar 

  • Schönenberger PM. Rengasil® (Pirprofen) als Beispiel eines Analgetikums. Therapeutische Umschau 40: 709–712, 1983

    PubMed  Google Scholar 

  • Schönenberger PM, Marbet GA, Duckert F. A study on interactions between pirprofen, given in a high dosage, and phenprocoumon. In Nassonova (Ed.) Pirprofen (Rengasil®) — an update, pp. 28–32, Hans Huber, Bern, 1984

    Google Scholar 

  • Sekker W, Schönmehl W, Rohde HJ, Brackertz D. Klinische Prüfung von Pirprofen und Naproxen bei Patienten mit Gon- und Coxarthrosen. Fortschritte der Medizin 103: 182–184, 1985

    PubMed  CAS  Google Scholar 

  • Serry MM. Pirprofen and indomethacin in rheumatoid arthritis — a double-blind three week trial. In van der Korst (Ed.) Pirprofen in the light of recent experience, pp. 66–75, Hans Huber, Bern, 1985

    Google Scholar 

  • Sigidin YA. Monotherapy with pirprofen and piroxicam in rheumatoid arthritis — a multicentre, double-blind trial versus placebo. In Nassonova (Ed.) Pirprofen (Rengasil®)— an update, pp. 54–62, Hans Huber, Bern, 1984

    Google Scholar 

  • Singleton CM, Wild JH. A double-blind comparison of aspirin and pirprofen in the treatment of rheumatoid arthritis. Journal of Rheumatology 7: 865–870, 1980

    PubMed  CAS  Google Scholar 

  • Sioufi A, Colussi D, Caron C, Schoeller JP, Guibert J. Effet de trois anti-acides sur la biodisponibilité du pirprofène. Thérapie 39: 23–27, 1984

    PubMed  CAS  Google Scholar 

  • Sörgel F, Hemmerlein M, Lang E. Wirkung von Pirprofen und Indometacin auf die Effekte von Oxprenolol und Furosemid. Arzneimittel-Forschung 34: 1330–1332, 1984

    PubMed  Google Scholar 

  • Sörgel F, Lang E. Effects of pirprofen and indomethacin on the diuretic and natriuretic activity of furosemide. In Nassonova (Ed.) Pirprofen (Rengasil®) — an update, pp. 33–39, Hans Huber, Bern, 1984

    Google Scholar 

  • Sperr W. The analgesic effect of pirprofen, as compared with pentazocine and placebo, following oral surgery. In van der Korst (Ed.) A new antirheumatic-analgesic agent: pirprofen (Rengasil®), pp. 22–27, Hans Huber, Bern, 1981

    Google Scholar 

  • Steinetz BG, Colombo C, Butler MC, O’Byrne E, Steele RE. Animal models of osteoarthritis: possible applications in a drug development program. Current Therapeutic Research 30 (Suppl.): 860–875, 1981

    Google Scholar 

  • Storck U, Hilgert A, Vetter O, Goebel KM. Clinical experience with pirprofen in the management of rheumatic diseases. Abstract no. 571 presented at the 10th European Congress of Rheumatology, Moscow, 26 Jun–2 Jul, 1983

  • Taller AJ. Die Behandlung der Periarthritis humeroscapularis mit Pirprofen: interindividuelle Doppelblindstudie an ambulanten Patienten. Fortschritte der Medizin 103: 197–199, 1985

    PubMed  CAS  Google Scholar 

  • Tausch G, Nekora A. Maintenance therapy with pirprofen and indomethacin in rheumatoid arthritis. In Korst (Ed.) Pirprofen in the treatment of pain and inflammation, pp. 44–51, Hans Huber, Bern, 1982

    Google Scholar 

  • Thompson TA, Borman CH, Goodblatt RS, Roth WJ. Effects of aspirin on 14C-pirprofen disposition in rats. Journal of Pharmaceutical Sciences 68: 996–998, 1979

    PubMed  CAS  Google Scholar 

  • Tsurumi K, Fujimura H. Effect of anti-inflammatory drugs on endotoxin-induced diarrhoea in mice. Japanese Journal of Pharmacology 33: 165–173, 1983

    PubMed  CAS  Google Scholar 

  • Tsurumi K, Kyuki K, Niwa M, Maki E, Fujimura H. Anti-inflammatory, analgesic and antipyretic activities of pirprofen. Pharmacometrics 24: 85–103, 1982a

    CAS  Google Scholar 

  • Tsurumi K, Kyuki K, Okada K, Mibu H, Fujimura H. Effect of pirprofen, 2-[2-chloro-4 (3-pyrrolinyl)-phenyl]-propionic acid, on acute inflammatory reactions and prostaglandin biosynthesis. Pharmacometrics 24: 71–83, 1982b

    CAS  Google Scholar 

  • Tsurumi K, Mibu H, Hasegawa J, Fujimura H. Effect of pirprofen on leucocyte migration and platelet aggregation. Pharmacometrics 25: 331–337, 1983

    CAS  Google Scholar 

  • Tsurumi K, Togawa Y, Okada K, Fujimura H. Drug interactions of pirprofen. Pharmacometrics 24: 105–112, 1982c

    CAS  Google Scholar 

  • Valdez Rojas S, de Alva Martin J. Tratamiento de esguinces del tobillo con pirprofen. Compendium de Investigaciones Clinicas Latinoamericanas 5: 12–15, 1985

    Google Scholar 

  • Valencia del Riego J, Vargas de la Llata R, Alvarez RC. Analgesia con pirprofen en el postoperatorio de cirugia general. Investigatión Médica International 12: 169–172, 1985

    Google Scholar 

  • Vane JR. Mode of action of aspirin and similar compounds. In Robinson & Vane (Eds) Prostaglandin synthetase inhibitors, pp. 155–163, Raven Press, New York, 1974

    Google Scholar 

  • Vazquez RU. Pirprofen en cirugia bucal. Investigatión Médica International 12: 173–175, 1985

    Google Scholar 

  • von Manteuffel G, Herbert V, Storck U, Hilgert A, Vetter O, et al. Symptomatische Langzeittherapie der Polyarthrose mit Pirprofen. Fortschritte der Medizin 103: 185–188, 1985

    Google Scholar 

  • Wilhelmi G. Effect of C21,524-Su (Pirprofen) on spontaneous osteoarthrosis in the mouse. Pharmacology 16: 268–272, 1978

    PubMed  CAS  Google Scholar 

  • Yamamoto H, Ozaki M, Kishioka S, Iguchi Y, Takeuchi K, et al. The general pharmacological actions of 2-[3-chloro-4-(3-pyrrolin-l-yl) -phenyl]-propionic acid (pirprofen) (1). Pharmacometrics 24: 751–766, 1982a

    CAS  Google Scholar 

  • Yamamoto H, Ozaki M, Kishioka S, Iguchi Y, Takeuchi K, et al. The general pharmacological actions of 2-[3-chloro-4-(3-pyrrolin-l-yl) -phenyl]-propionic acid (pirprofen) (3). Pharmacometrics 24: 791–806, 1982b

    CAS  Google Scholar 

  • Yamamoto H, Ozaki M, Kishioka S, Iguchi Y, Tamura S. Tolerance liability to antinociceptive effect of 2-[3-chloro-4-(3-pyrrolin-l-yl) -phenyl]-propionic acid (pirprofen) in rat’s hindpaw pressure test, compared with that of indomethacin. Pharmacometrics 29: 259–265, 1985a

    CAS  Google Scholar 

  • Yamamoto H, Ozaki M, Kishioka S, Iguchi Y, Tamura S. Tolerance liability to inhibitory effect on acetic acid-induced writhing of 2-[3-chloro-4-(3-pyrrolin-l-yl)-phenyl]-propionic acid (pirprofen) in rats. Pharmacometrics 29: 267–275, 1985b

    CAS  Google Scholar 

  • Yamamoto H, Ozaki M, Kishioka S, Iguchi Y, Yamamoto C. Antinociceptive effect and tolerance liability to its effect of 2-[3-chloro-4-(3-pyrrolin-l-yl) -phenyl]-propionic acid (pirprofen) in rats. Pharmacometrics 26: 469–479, 1983b

    CAS  Google Scholar 

  • Yamamoto H, Ozaki M, Kishioka S, Iguchi Y, Yamamoto C. The physical dependence liability of morphine-type on 2-[3-chloro-4-(3-pyrrolin-l-yl) -phenyl]-propionic acid (pirprofen) in rats. Pharmacometrics 26: 647–657, 1983a

    CAS  Google Scholar 

  • Yamamoto H, Ozaki M, Kishioka S, Iguchi Y, Yamamoto C. The physical dependence liability of barbital-type on 2-[3-chloro-4-(3-pyrrolin-l-yl) -phenyl]-propionic acid (Pirprofen) in rats. Pharmacometrics 26: 677–686, 1983c

    CAS  Google Scholar 

  • Younis MN, Moussa AA, Sultan MA, Abdalla AH. An evaluation of pirprofen in the treatment of primary dysmenorrhoea. In van der Korst (Ed.) Pirprofen in the light of recent experience, pp. 86–91, Hans Huber, Bern, 1985

    Google Scholar 

  • Zaghloul MA. Clinical experience with Rengasil (pirprofen) in the treatment of osteoarthritis of the knee joint. Abstract presented at the 16th International Congress of Rheumatology, Sydney, 19–25 May, 1985

Download references

Author information

Authors and Affiliations

  1. ADIS Drug Information Services, Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand

    Peter A. Todd & Rosemary Beresford

Authors
  1. Peter A. Todd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosemary Beresford
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Various sections of the manuscript reviewed by: H. Berry, Department of Rheumatology and Rehabilitation, King’s College Hospital, London, England; B. Dolane, Orthopädische Universitätsklinik, Basel, Switzerland; F.D. Hart, Harley Street, London, England; A. Hedges, Department of Clinical Pharmacology, St Bartholomew’s Hospital, London, England; I. Jajic, Faculty of Medicine, University of Zagreb, Zagreb, Yugoslavia; S.H. Roth, St Luke’s Hospital Medical Center, Phoenix, Arizona, USA; G. Tausch, Krankenhaus Lainz, Vienna, Austria; H. Yamamoto, Wakayama Medical College, Wakayama, Japan.

‘Rengacil’, ‘Rengasil’, ‘Seflenyl’ (Ciba-Geigy).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Todd, P.A., Beresford, R. Pirprofen. Drugs 32, 509–537 (1986). https://doi.org/10.2165/00003495-198632060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198632060-00003

Keywords

Search

Navigation